Fagan Associates, Inc. Vertex Pharmaceuticals Inc Transaction History

Fagan Associates, Inc.

$682 Million
Q3 2025

A detailed history of Fagan Associates, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fagan Associates, Inc. holds 26,306 shares of VRTX stock, worth $11.4 Million. This represents 1.51% of its overall portfolio holdings.

Number of Shares

26,306

Previous 26,195 0.42%

Holding current value

$11.4 Million

Previous $11.7 Million 11.66%

% of portfolio

1.51%

Previous 1.91%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$366.54 - $479.53 $40,685 - $53,227	111 Added 0.42%	26,306 $10.3 Million
Q2 2025 Aug 07, 2025	SELL	$421.16 - $509.5 $37,904 - $45,855	-90 Reduced 0.34%	26,195 $11.7 Million
Q1 2025 May 05, 2025	SELL	$402.49 - $513.76 $93,780 - $119,706	-233 Reduced 0.88%	26,285 $12.7 Million
Q4 2024 Jan 31, 2025	BUY	$396.64 - $516.74 $36,887 - $48,056	93 Added 0.35%	26,518 $10.7 Million
Q3 2024 Nov 12, 2024	SELL	$460.0 - $505.78 $32,200 - $35,404	-70 Reduced 0.26%	26,425 $12.3 Million

Q2 2024 Aug 09, 2024	BUY	$392.81 - $485.53 $218,795 - $270,440	557 Added 2.15%	26,495 $12.4 Million
Q1 2024 May 06, 2024	BUY	$407.69 - $446.08 $202,214 - $221,255	496 Added 1.95%	25,938 $10.8 Million
Q4 2023 Feb 07, 2024	BUY	$343.0 - $410.68 $121,765 - $145,791	355 Added 1.42%	25,442 $10.4 Million
Q3 2023 Oct 31, 2023	BUY	$338.18 - $362.46 $172,471 - $184,854	510 Added 2.08%	25,087 $8.72 Million
Q2 2023 Aug 08, 2023	BUY	$314.42 - $351.91 $136,143 - $152,377	433 Added 1.79%	24,577 $8.65 Million
Q1 2023 May 03, 2023	SELL	$283.23 - $323.1 $27,473 - $31,340	-97 Reduced 0.4%	24,144 $7.61 Million
Q4 2022 Jan 25, 2023	BUY	$285.76 - $321.48 $71,440 - $80,370	250 Added 1.04%	24,241 $0
Q3 2022 Nov 01, 2022	BUY	$273.83 - $305.53 $73,934 - $82,493	270 Added 1.14%	23,991 $6.95 Million
Q2 2022 Aug 03, 2022	SELL	$234.96 - $292.55 $511,742 - $637,173	-2,178 Reduced 8.41%	23,721 $6.68 Million
Q1 2022 May 06, 2022	BUY	$221.42 - $260.97 $549,121 - $647,205	2,480 Added 10.59%	25,899 $6.76 Million
Q4 2021 Feb 08, 2022	BUY	$177.01 - $223.45 $533,154 - $673,031	3,012 Added 14.76%	23,419 $5.14 Million
Q3 2021 Nov 09, 2021	SELL	$181.39 - $202.99 $187,738 - $210,094	-1,035 Reduced 4.83%	20,407 $3.7 Million
Q2 2021 Aug 06, 2021	BUY	$187.49 - $221.1 $591,905 - $698,012	3,157 Added 17.27%	21,442 $4.32 Million
Q1 2021 May 06, 2021	BUY	$207.02 - $241.31 $3.02 Million - $3.52 Million	14,570 Added 392.19%	18,285 $3.93 Million
Q4 2020 Feb 08, 2021	BUY	$207.01 - $276.09 $769,042 - $1.03 Million	3,715 New	3,715 $878,000

Others Institutions Holding VRTX

# of Institutions

1,789

Shares Held

231M

Call Options Held

1.83M

Put Options Held

1.21M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $111B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fagan Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fagan Associates, Inc. with notifications on news.

Account

Fagan Associates, Inc. Vertex Pharmaceuticals Inc Transaction History